Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2019

View Archived Issues

Indole-2-carboxamides show oral bioavailability and efficacy in M. abscessus-infected mice

Missense mutation in SLC9A7 causes multigenerational nonsyndromic X-linked intellectual disability

Tizona initiates phase I/Ib study of TTX-030 in advanced cancers

Merck & Co. optimizes alpha7 nicotinic receptor PAM for cognitive disorders

Antipsychotics target bacterial virulence factor

PD biomarkers pass smell test

Nemo stabilizes Tregs

IDO1 heme antagonist GS-4361 is a potent and selective candidate

AACR 2019: Clinical trials begin to solidify CAR T successes

Potent, oral IAP antagonist TQB-3728 shows in vitro and in vivo antitumor activity

Histone deacetylase inhibitor AES-135 shows preclinical efficacy against pancreatic cancer

FDA issues complete response letter for midazolam nasal spray

Bemcentinib plus low-dose cytarabine achieves efficacy endpoint in patients with AML

Bristol-Myers Squibb presents hSTING agonists

Recida initiates phase I study of LpxC inhibitor RC-01

Symberix divulges GUS inhibitors for diarrhea

Eli Lilly and Company disclose MAP3K5 inhibitors

Incyte describes new MAP4K1 inhibitors

TaiwanJ Pharmaceuticals divulges E-NPP 2 inhibitors

Columbia University conducts exploratory evaluation of [11C]-NOP46 PET tracer for chronic pain

Enrollment open in phase II study of bimiralisib for HNSCC with NOTCH1 LOF mutations

European Commission approves Ajovy for migraine prophylaxis

MediciNova reports subgroup analysis from phase IIb SPRINT-MS study of MN-166 in progressive MS

Nanoliposomal ATR inhibitors presented for cancer therapy

Asceniv approved by FDA to treat humoral immunodeficiency disease

FDA approves reintroduction of Zelnorm